Agios Pharmaceuticals, Inc. (AGIO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AGIO Revenue Growth
Revenue Breakdown (FY 2025)
AGIO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AGIO Revenue Analysis (2014–2025)
As of May 8, 2026, Agios Pharmaceuticals, Inc. (AGIO) generated trailing twelve-month (TTM) revenue of $66.0 million, reflecting explosive growth of +137.7% year-over-year. The most recent quarter (Q1 2026) recorded $20.7 million in revenue, up 3.9% sequentially.
Looking at the longer-term picture, AGIO's historical revenue data shows a 3-year CAGR of +56.0%. The company achieved its highest annual revenue of $117.9 million in 2019.
Revenue diversification analysis shows AGIO's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IONS (+47.5% YoY), PTCT (-53.3% YoY), and RARE (+13.3% YoY), AGIO has outperformed the peer group in terms of revenue growth. Compare AGIO vs IONS →
AGIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AGIOCurrent | $66M | +137.7% | - | -873.9% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
AGIO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $54.0M | +48.0% | $42.5M | 78.7% | $-472,132,000 | -873.9% |
| 2024 | $36.5M | +36.1% | $32.3M | 88.6% | $-425,737,000 | -1166.5% |
| 2023 | $26.8M | +88.4% | $17.3M | 64.6% | $-391,487,000 | -1459.5% |
| 2022 | $14.2M | - | $12.5M | 88.0% | $-389,047,000 | -2732.1% |
| 2021 | $0 | - | $-18,777,000 | - | $-378,418,000 | - |
| 2020 | $0 | -100.0% | $-18,772,000 | - | $-335,916,000 | - |
| 2019 | $117.9M | +24.9% | $116.6M | 98.9% | $-426,333,000 | -361.6% |
| 2018 | $94.4M | +119.4% | $93.0M | 98.5% | $-362,479,000 | -384.0% |
| 2017 | $43.0M | -38.5% | $-249,670,000 | -580.5% | $-320,794,000 | -745.8% |
| 2016 | $69.9M | +18.2% | $-150,271,000 | -215.0% | $-200,985,000 | -287.6% |
See AGIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AGIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AGIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAGIO — Frequently Asked Questions
Quick answers to the most common questions about buying AGIO stock.
Is AGIO's revenue growth accelerating or slowing?
AGIO revenue is accelerating at +137.7% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $66M. Growth momentum has increased versus prior periods.
What is AGIO's long-term revenue growth rate?
Agios Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +137.7% is above this long-term average.
How is AGIO's revenue distributed by segment?
AGIO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.